Comments
Drug firm Alembic Pharmaceuticals on Wednesday reported more than two-fold jump in consolidated net profit to ₹301.46 crore for the quarter ended on June 30, 2020, mainly on account of robust sales in international markets.
The company had posted a net profit of ₹123.72 crore for the corresponding period of the previous fiscal, Alembic Pharmaceuticals said in a filing to BSE.
Consolidated revenue from operations of the company stood at ₹1,341.32 crore for the period under consideration against ₹948.91 crore for the same period year ago, it added.
“It was an excellent quarter for the company backed by growth in all the international markets. Despite exceptionally, challenging circumstances, the operating teams ensured profitability and growth,” said Alembic Pharmaceuticals MD Pranav Amin.
International formulations revenue grew 70 per cent to ₹771 crore in the quarter, the company said.
Shares of Alembic Pharmaceuticals were trading at ₹1,010.15 on BSE, up 1.55 per cent from the previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.